Medical Cannabis Cancer Research — Evidence, Clinical Trials & Patient Outcomes

Executive Summary

Medical cannabis has emerged as a significant area of cancer research, with mounting evidence suggesting therapeutic benefits for symptom management, though definitive proof of anti-tumor effects in humans remains elusive. Recent studies demonstrate that cancer patients using medical cannabis report substantial relief from chemotherapy-induced nausea, chronic pain, appetite loss, and sleep disturbances. As of September 2026, more than 38 states have legalized medical cannabis programs that include cancer as a qualifying condition, while federal Schedule I classification continues to restrict large-scale clinical trials. The National Cancer Institute acknowledges cannabinoids' potential palliative properties, yet the FDA has approved only three synthetic cannabinoid medications for cancer-related indications. This research landscape sits at the intersection of patient demand, regulatory barriers, and evolving scientific understanding—with billions of dollars in potential market value and millions of patients seeking alternatives to conventional symptom management protocols.

Why Medical Cannabis Cancer Research Matters

Cancer affects approximately 1.9 million Americans annually, with treatment side effects often as debilitating as the disease itself. The American Cancer Society estimates that cancer-related healthcare costs exceed $200 billion per year in the United States alone. Traditional symptom management approaches—including opioid analgesics for pain and pharmaceutical antiemetics for nausea—carry significant side effect profiles and addiction risks that have driven patient interest in cannabis-based alternatives. For oncologists, the question is clinical: does medical cannabis provide measurable symptom relief with acceptable safety profiles? Patient surveys consistently show 40-60% of cancer patients either currently use or have considered using cannabis products, yet physicians often lack evidence-based guidance for recommendations. The gap between patient adoption and clinical evidence creates liability concerns and undermines the physician-patient relationship. For researchers, federal restrictions present the central challenge. The DEA maintains cannabis as a Schedule I controlled substance under 21 U.S.C. § 812, requiring special licensing and limiting access to research-grade material. The National Institute on Drug Abuse historically served as the sole legal source of cannabis for federally funded research, providing material that researchers describe as lower in potency and cannabinoid diversity than products patients actually use. For the cannabis industry, cancer represents both the most sympathetic patient population and the highest-stakes market opportunity. Multi-state operators including Curaleaf, Trulieve, and Green Thumb Industries have invested in patient education programs and product formulations targeting oncology patients. The medical cannabis market segment focused on cancer patients was valued at approximately $2.8 billion in 2025, according to industry analysts. For patients, the stakes are immediate and personal. Chemotherapy-induced nausea can prevent patients from completing treatment protocols. Opioid-based pain management carries overdose risks that killed more than 80,000 Americans in 2025. Appetite stimulation matters when cachexia—severe weight loss—directly correlates with mortality. Cannabis represents a potential tool with thousands of years of historical use and a safety profile that includes zero recorded fatal overdoses.

Background and History: From Ancient Medicine to Modern Clinical Trials

Cannabis has been used medicinally for cancer-related symptoms for millennia, but rigorous scientific investigation began only in the late 20th century.

Ancient and Pre-Modern Use (2700 BCE - 1900 CE)

Chinese Emperor Shen Nung's pharmacopeia from approximately 2700 BCE referenced cannabis for various ailments. Ancient Egyptian medical texts described cannabis preparations for inflammation and pain. However, specific documentation of cannabis use for cancer symptoms remains sparse in historical records, largely because cancer as a distinct disease category was poorly understood until modern pathology emerged. In 19th century Western medicine, cannabis tinctures appeared in the United States Pharmacopeia from 1850 to 1942. Physicians prescribed cannabis extracts for pain management and as appetite stimulants, though cancer-specific applications were not systematically documented. The 1937 Marihuana Tax Act effectively ended legal medical cannabis use in the United States, and the 1970 Controlled Substances Act codified its Schedule I status.

Discovery of the Endocannabinoid System (1964-1990s)

Modern cannabis research began when Israeli chemist Raphael Mechoulam isolated and synthesized THC in 1964. This breakthrough enabled pharmacological studies of specific cannabinoids rather than whole-plant preparations. In 1988, researchers at the St. Louis University School of Medicine discovered the first cannabinoid receptor (later named CB1) in rat brains. The 1993 discovery of the CB2 receptor, found primarily in immune system tissues, suggested cannabinoids might influence immune function and inflammation—both relevant to cancer biology. The identification of endogenous cannabinoids (endocannabinoids) including anandamide and 2-AG revealed that humans possess a native signaling system that cannabis compounds interact with. This endocannabinoid system regulates pain perception, appetite, mood, and immune response—all relevant to cancer symptom management.

Early Clinical Applications (1975-2000)

The first FDA-approved cannabinoid medication, dronabinol (synthetic THC marketed as Marinol), received approval in 1985 specifically for chemotherapy-induced nausea and vomiting. The approval was based on clinical trials conducted in the late 1970s and early 1980s showing THC reduced vomiting in cancer patients receiving chemotherapy. In 1992, the FDA approved dronabinol for AIDS-related anorexia, establishing appetite stimulation as a recognized cannabinoid effect. Nabilone (Cesamet), another synthetic cannabinoid, received FDA approval in 1985 for chemotherapy-induced nausea. These approvals represented the first official recognition that cannabinoids offered therapeutic value for cancer patients, though both medications delivered isolated synthetic compounds rather than whole-plant cannabis.

State Medical Cannabis Programs (1996-2010)

California's Proposition 215 in 1996 created the first modern state medical cannabis program, explicitly listing cancer as a qualifying condition. By 2010, 15 states had enacted medical cannabis laws, with cancer appearing as a qualifying condition in every program. This state-level policy shift occurred despite ongoing federal prohibition and limited clinical evidence, driven largely by patient advocacy and anecdotal reports of benefit. The divergence between state and federal law created a research paradox: millions of patients gained legal access to cannabis under state law, yet researchers faced federal barriers to studying the products patients actually used. The University of California Center for Medicinal Cannabis Research, established in 2000, represented one of the first state-funded efforts to conduct rigorous clinical trials, though initial studies focused primarily on pain rather than cancer-specific outcomes.

Preclinical Cancer Research (2000-2015)

Laboratory studies during this period generated significant interest in cannabinoids' potential anti-tumor properties. Research published in journals including Cancer Research and the British Journal of Pharmacology demonstrated that cannabinoids could inhibit tumor growth, induce cancer cell death (apoptosis), and prevent angiogenesis (blood vessel formation that feeds tumors) in cell cultures and animal models. A 2006 study published in the Journal of Clinical Investigation showed that THC reduced tumor growth in mice with glioblastoma (aggressive brain cancer). Spanish researcher Manuel Guzmán's laboratory published multiple papers demonstrating cannabinoid effects on various cancer cell lines. However, these preclinical findings did not translate into human clinical trials, partly due to regulatory barriers and partly due to the significant gap between cell culture results and human therapeutic applications.

Modern Clinical Research Era (2015-Present)

The 2018 Farm Bill legalized hemp (cannabis with less than 0.3% THC), creating new research opportunities for CBD and other non-intoxicating cannabinoids. The DEA expanded the number of licensed cannabis manufacturers for research purposes in 2021, though implementation remained slow. As of 2026, the National Cancer Institute's website acknowledges that cannabinoids may help with cancer symptoms and treatment side effects, while noting that no large-scale clinical trials have proven anti-tumor effects in humans. Israel has emerged as a global leader in medical cannabis research, with government support for clinical trials and a national medical cannabis program serving more than 100,000 patients, many with cancer diagnoses. Canadian legalization in 2018 similarly expanded research opportunities. In the United States, observational studies and patient surveys have proliferated, though randomized controlled trials remain limited. The September 2026 study reported by Yahoo represents the latest in a growing body of observational research showing patient-reported benefits, though methodological limitations continue to prevent definitive clinical conclusions.

Key Players in Medical Cannabis Cancer Research

National Cancer Institute (NCI)

The NCI, part of the National Institutes of Health, maintains a comprehensive information page on cannabis and cannabinoids for healthcare professionals. The institute acknowledges preclinical evidence of anti-tumor effects while emphasizing the lack of large-scale human trials. NCI has not directly funded major cannabis clinical trials for cancer, though it has supported some observational research. The institute's cautious position reflects both scientific uncertainty and federal legal constraints.

National Institute on Drug Abuse (NIDA)

NIDA historically controlled the supply of research-grade cannabis through a contract with the University of Mississippi. This monopoly created bottlenecks and quality concerns, as researchers reported the available material did not reflect the potency or cannabinoid profiles of products patients use. NIDA's mission focuses on substance abuse rather than therapeutic applications, creating a structural tension in cannabis research policy. Recent policy changes have begun to diversify the supply chain, though implementation has been gradual.

Food and Drug Administration (FDA)

The FDA has approved three cannabinoid medications: dronabinol (Marinol), nabilone (Cesamet), and cannabidiol (Epidiolex, approved in 2018 for epilepsy). The agency maintains that cannabis itself cannot be approved as a medicine because the plant contains variable compounds and dosing cannot be standardized. The FDA's drug approval pathway requires extensive clinical trials demonstrating safety and efficacy—a standard that whole-plant cannabis has not met for cancer indications. The agency has issued warning letters to companies making unsubstantiated cancer treatment claims about cannabis products.

Drug Enforcement Administration (DEA)

The DEA's classification of cannabis as Schedule I under the Controlled Substances Act defines it as having no accepted medical use and high abuse potential. This classification directly contradicts state medical cannabis programs and creates the legal framework that restricts research. The DEA has rejected multiple petitions to reschedule cannabis, most recently in 2023, though the agency announced in 2024 that it was reviewing a potential move to Schedule III. As of September 2026, cannabis remains Schedule I, though rescheduling discussions continue.

Academic Research Centers

Several institutions have established dedicated cannabis research programs. The University of California Center for Medicinal Cannabis Research has published studies on pain and other symptoms. Johns Hopkins University established a Cannabis Science Laboratory in 2020. Harvard Medical School researchers have conducted surveys of cancer patients using cannabis. However, no major cancer center has established a large-scale clinical trial program specifically for cannabis in oncology, reflecting both funding challenges and regulatory complexity.

International Researchers

Israeli researcher Raphael Mechoulam, who died in 2023, pioneered cannabinoid science over six decades. Spanish researcher Manuel Guzmán has published extensively on cannabinoids and brain tumors. Canadian researchers have conducted clinical trials following national legalization. British company GW Pharmaceuticals (acquired by Jazz Pharmaceuticals in 2021) developed Sativex, a cannabis-derived oromucosal spray approved in multiple countries (though not the United States) for cancer pain and multiple sclerosis spasticity.

Patient Advocacy Organizations

Americans for Safe Access has advocated for medical cannabis access and research since 2002. The Marijuana Policy Project has supported state-level medical cannabis legislation. Cancer-specific advocacy has come from individual patients and families rather than major cancer organizations, which have generally maintained cautious positions pending more definitive research.

Cannabis Industry

Multi-state operators including Curaleaf, Trulieve, Green Thumb Industries, and Cresco Labs have developed product lines marketed to medical patients, including those with cancer. However, industry-funded research remains limited, partly due to federal restrictions and partly due to the industry's focus on market expansion over clinical validation. Some companies have established partnerships with academic institutions, though these collaborations have not yet produced major published trials.

Legal and Regulatory Framework

The legal landscape for medical cannabis cancer research is defined by the tension between federal prohibition and state-level medical programs. At the federal level, 21 U.S.C. § 812 establishes the Controlled Substances Act scheduling system. Cannabis remains Schedule I, defined as having high abuse potential, no currently accepted medical use, and lack of accepted safety for use under medical supervision. This classification applies regardless of state law. Researchers must obtain a Schedule I license from the DEA to conduct studies, a process that can take years and requires extensive security measures. The 2018 Farm Bill (Agriculture Improvement Act of 2018) removed hemp from Schedule I, defining hemp as cannabis with no more than 0.3% delta-9 THC on a dry weight basis. This created a legal pathway for CBD research, though CBD products remain subject to FDA regulation and cannot be marketed as dietary supplements or with therapeutic claims without FDA approval. State medical cannabis laws vary significantly but share common elements. Qualifying conditions lists almost universally include cancer. States including California, Colorado, Massachusetts, Michigan, and Illinois have established regulatory frameworks for cultivation, testing, and dispensing. However, state legalization does not override federal law, creating ongoing legal uncertainty for researchers, healthcare providers, and patients. The Rohrabacher-Farr Amendment (later Rohrabacher-Blumenauer), first passed in 2014 and renewed in subsequent appropriations bills, prohibits the Department of Justice from using funds to prevent states from implementing medical cannabis laws. This provides some protection for state programs but does not legalize cannabis or explicitly protect research activities. Clinical trial regulations add additional complexity. Studies involving cannabis must comply with FDA Investigational New Drug (IND) application requirements, DEA licensing, institutional review board approval, and often state-level research permits. The combination of requirements has deterred many researchers and limited the scope of studies that do proceed.

Current State of the Science: What Research Shows

The evidence base for medical cannabis in cancer care is strongest for symptom management and weakest for direct anti-tumor effects.

Chemotherapy-Induced Nausea and Vomiting

Multiple clinical trials from the 1980s and 1990s demonstrated that THC reduces chemotherapy-induced nausea and vomiting. A 2015 systematic review published in the Journal of Clinical Oncology analyzed 28 randomized controlled trials and concluded that cannabinoids were more effective than placebo and comparable to conventional antiemetics for this indication. However, most studies used synthetic cannabinoids (dronabinol or nabilone) rather than whole-plant cannabis, and many were conducted before modern antiemetic drugs like 5-HT3 antagonists became standard. Recent observational studies suggest patients prefer inhaled or whole-plant cannabis over synthetic pills, reporting faster onset and better symptom control. However, these studies lack the rigor of randomized trials and may reflect placebo effects or patient expectations.

Cancer Pain

Pain is the most common symptom prompting cannabis use among cancer patients. A 2017 National Academies of Sciences, Engineering, and Medicine report concluded there is substantial evidence that cannabis is effective for chronic pain in adults. However, most pain studies have focused on non-cancer pain, and cancer pain often has distinct mechanisms. A 2019 study published in the Journal of Pain and Symptom Management followed 324 cancer patients using medical cannabis and found that 95% reported improvement in symptoms, with pain being the most commonly improved. However, the study was observational without a control group. Randomized controlled trials specifically for cancer pain remain limited, though Sativex has shown efficacy for cancer pain in trials conducted outside the United States.

Appetite and Cachexia

THC's appetite-stimulating effects are well-documented, leading to dronabinol's FDA approval for AIDS-related anorexia. Cancer-related cachexia (wasting syndrome) affects up to 80% of advanced cancer patients and directly contributes to mortality. Small studies have shown that THC can increase appetite and food intake in cancer patients, though effects on weight gain and survival have been inconsistent. A 2011 study published in Annals of Oncology found that cannabis extract did not improve appetite or quality of life more than placebo in cancer patients with cachexia, suggesting that appetite stimulation alone may not address the complex metabolic changes underlying cancer cachexia.

Sleep and Anxiety

Cancer patients frequently report sleep disturbances and anxiety, both from the disease itself and from treatment side effects. Patient surveys consistently show that cannabis users report improved sleep quality. A 2019 study in the Journal of Clinical Sleep Medicine found that 84% of medical cannabis users reported improved sleep, though the study included various conditions, not only cancer. CBD has shown anxiolytic (anxiety-reducing) properties in preclinical studies and small human trials, though large-scale studies in cancer populations are lacking. The interaction between THC and CBD may be important, as some research suggests CBD can mitigate THC-induced anxiety.

Anti-Tumor Effects: The Preclinical-Clinical Gap

Laboratory studies have demonstrated that cannabinoids can kill cancer cells, inhibit tumor growth, and prevent metastasis in cell cultures and animal models. Mechanisms include inducing apoptosis (programmed cell death), inhibiting angiogenesis (blood vessel formation), and reducing cell proliferation. These effects have been shown across multiple cancer types including glioblastoma, breast cancer, lung cancer, and prostate cancer. However, no large-scale clinical trials have demonstrated that cannabinoids shrink tumors or extend survival in human cancer patients. The doses used in preclinical studies often far exceed what humans could safely consume. A 2019 review in the journal Cancers concluded that while preclinical evidence is promising, clinical translation remains speculative. Small pilot studies have explored cannabinoids for glioblastoma. A 2021 phase 2 trial published in Neuro-Oncology combined THC and CBD with temozolomide chemotherapy in glioblastoma patients and found the combination was safe but did not significantly improve survival compared to historical controls. The study was too small to draw definitive conclusions but represents one of the few attempts to test cannabinoids as anti-cancer agents in humans.

The September 2026 Study

The study triggering this analysis, reported in September 2026, adds to the observational literature showing patient-reported symptom relief. While specific methodological details were not available in the initial news report, such studies typically survey cancer patients using medical cannabis and document self-reported changes in symptoms including pain, nausea, appetite, and sleep. These studies provide valuable real-world data but cannot establish causation or rule out placebo effects without randomized controlled designs.

Market and Business Implications

The medical cannabis market segment serving cancer patients represents billions in annual revenue and continues to grow despite regulatory uncertainty. Multi-state operators have identified cancer patients as a priority demographic, developing product lines with specific cannabinoid ratios and delivery methods. Tinctures and capsules appeal to patients seeking precise dosing and avoiding inhalation. Topical products target localized pain. High-CBD, low-THC formulations attract patients concerned about intoxication. Pricing varies significantly by state and product type. A month's supply of medical cannabis products for symptom management typically costs $200-600, often not covered by insurance due to federal prohibition. This creates access barriers for patients on fixed incomes, particularly those unable to work due to illness. The potential rescheduling of cannabis to Schedule III, discussed in 2024-2026, would have significant business implications. Schedule III status would allow cannabis businesses to deduct normal business expenses under federal tax law, eliminating the burden of Internal Revenue Code Section 280E, which currently prohibits such deductions for Schedule I substances. This could improve profitability and potentially lower patient costs. However, Schedule III would not legalize cannabis or automatically enable insurance coverage. Medicare and Medicaid cannot cover Schedule I substances, and it remains unclear whether Schedule III status would change this for whole-plant cannabis (as opposed to FDA-approved cannabinoid medications). Investment in cannabis research by industry remains modest compared to market size. Most cannabis companies are privately held or trade on Canadian exchanges, limiting capital available for expensive clinical trials. Pharmaceutical companies have largely avoided the space due to federal prohibition, though some have explored synthetic cannabinoids or specific isolated compounds. The international market presents different dynamics. Canadian licensed producers including Canopy Growth and Aurora Cannabis have invested in medical cannabis research and international expansion. Israeli companies including Tikun Olam and Panaxia have developed medical cannabis products with clinical data. European markets are opening gradually, with Germany's medical cannabis program serving tens of thousands of patients.

What Experts Say

The medical and scientific community remains divided on medical cannabis for cancer, with positions ranging from cautious support for symptom management to skepticism about therapeutic claims. The American Society of Clinical Oncology published a position statement in 2017 supporting research into cannabis for cancer symptom management while emphasizing the need for rigorous clinical trials. The organization noted that oncologists frequently receive questions from patients about cannabis but lack evidence-based guidance for recommendations. According to the National Academies of Sciences, Engineering, and Medicine 2017 report, there is substantial evidence that cannabis is effective for chronic pain and conclusive evidence that cannabinoids are effective for chemotherapy-induced nausea and vomiting. However, the report noted that most evidence comes from studies of synthetic cannabinoids rather than whole-plant cannabis. Dr. Donald Abrams, an oncologist and cannabis researcher at the University of California, San Francisco, has stated in published interviews that cannabis appears to help cancer patients with symptom management and may allow reduction in opioid use. However, he has emphasized that cannabis should complement, not replace, conventional cancer treatment. The American Cancer Society's position, updated in 2022, states that the organization supports research into cannabis for cancer patients and believes that patients should have legal access in states with medical cannabis programs. However, the organization notes that more research is needed and that cannabis should not be used as a substitute for proven cancer treatments. Critics of medical cannabis research point to methodological limitations in existing studies, including small sample sizes, lack of placebo controls, and reliance on patient self-reporting. Some researchers have expressed concern that premature claims about cannabis curing cancer could lead patients to forgo effective conventional treatments. The National Cancer Institute's summary for health professionals, updated regularly, acknowledges that cannabinoids may have benefits for cancer patients but emphasizes that clinical evidence remains limited. The summary notes that while preclinical studies show anti-tumor effects, these have not been replicated in human trials. Patient advocacy perspectives differ from institutional medical positions. Many patients report that cannabis has improved their quality of life during cancer treatment, regardless of whether large-scale clinical trials have confirmed these benefits. Some advocates argue that the standard of evidence applied to cannabis exceeds that applied to many conventional supportive care interventions.

State-by-State Medical Cannabis Access for Cancer Patients

As of September 2026, 38 states plus the District of Columbia have legalized medical cannabis programs that include cancer as a qualifying condition.

California

California's Proposition 215 (1996) established the nation's first modern medical cannabis program. Cancer qualifies as a condition, and patients can possess up to 8 ounces of dried cannabis with a physician recommendation. The state has no cap on the number of dispensaries, and vertical integration is not required. California transitioned to a combined medical and adult-use market in 2018, though medical patients receive tax exemptions and can possess larger quantities than adult-use consumers.

Colorado

Colorado legalized medical cannabis in 2000 through Amendment 20. Cancer is a qualifying condition, and patients can possess up to 2 ounces of usable cannabis. The state allows patients to designate caregivers and permits home cultivation of up to 6 plants. Colorado's dual medical and adult-use market (adult-use legalized in 2012) maintains separate regulations, with medical patients accessing higher-potency products.

Florida

Florida's medical cannabis program, established by constitutional amendment in 2016, includes cancer as a qualifying condition. Patients can purchase up to 2.5 ounces of smokable cannabis every 35 days, plus additional non-smokable products. The state uses a vertical integration model with a limited number of licensed operators. Florida has one of the largest medical cannabis patient populations, exceeding 800,000 registered patients as of 2026.

Illinois

Illinois legalized medical cannabis in 2013, with cancer as a qualifying condition. Patients can possess up to 2.5 ounces every 14 days. The state transitioned to adult-use legalization in 2020 but maintains a separate medical program with lower taxes and higher possession limits. Illinois requires patients to register with the state and obtain a medical cannabis card.

Massachusetts

Massachusetts voters approved medical cannabis in 2012, with cancer qualifying. Patients can possess up to 10 ounces in their residence and up to 2.5 ounces outside the home. The state allows home cultivation of up to 6 plants for medical patients. Massachusetts legalized adult-use cannabis in 2016, creating a dual market with medical patients receiving tax benefits.

Michigan

Michigan's medical cannabis program (2008) includes cancer as a qualifying condition. Patients can possess up to 2.5 ounces of usable cannabis and cultivate up to 12 plants. The state legalized adult-use cannabis in 2018, but medical patients maintain higher possession limits and cultivation rights. Michigan has developed one of the most competitive cannabis markets in the nation.

New York

New York established a medical cannabis program in 2014, initially with restrictive regulations including no smokable flower and a limited number of vertically integrated operators. Cancer qualifies as a condition. The state significantly expanded the program in 2021 and legalized adult-use cannabis the same year. As of 2026, New York allows smokable flower for medical patients and has increased the number of licensed operators.

Ohio

Ohio's medical cannabis program launched in 2019 following 2016 legislation. Cancer is a qualifying condition, and patients can purchase up to 2.8 ounces every 90 days. The state does not allow home cultivation for medical patients and uses a competitive licensing system for cultivators, processors, and dispensaries. Ohio voters rejected adult-use legalization in 2023 but approved it in 2024, with sales beginning in 2025.

Pennsylvania

Pennsylvania's medical cannabis program (2016) includes cancer as a qualifying condition. Patients can purchase up to a 30-day supply as determined by their physician. The state initially prohibited smokable flower but reversed this restriction in 2021. Pennsylvania does not allow home cultivation and maintains a medical-only program without adult-use legalization as of 2026.

Texas

Texas operates one of the most restrictive medical cannabis programs in the nation. The Compassionate Use Program, established in 2015 and expanded in 2019 and 2021, includes cancer as a qualifying condition. However, the program limits THC content to 1% and restricts product forms. Patients must have a prescription (not just a recommendation) from a qualified physician. The program serves fewer than 50,000 patients statewide as of 2026.

States Without Medical Cannabis Programs

As of September 2026, 12 states have not legalized comprehensive medical cannabis programs: Idaho, Wyoming, Nebraska, Kansas, Wisconsin, Tennessee, Kentucky, South Carolina, North Carolina, Georgia, Alabama, and Indiana. Some of these states have limited CBD-only programs that do not provide meaningful access for cancer patients seeking THC-containing products. Cancer patients in these states must either relocate, travel to other states (which creates legal risks when transporting cannabis across state lines), or forgo legal access entirely.

What Comes Next: Research Priorities and Policy Developments

The future of medical cannabis cancer research depends on federal policy changes, funding priorities, and the design of rigorous clinical trials. The most immediate policy question is cannabis rescheduling. The DEA's consideration of moving cannabis to Schedule III, announced in 2024 and still under review as of September 2026, would not legalize cannabis but would reduce research barriers and change tax treatment for cannabis businesses. Schedule III substances can be researched with less restrictive licensing requirements than Schedule I. However, rescheduling would not automatically enable FDA approval of whole-plant cannabis or require insurance coverage. Congressional legislation remains another pathway. The SAFE Banking Act, which would protect financial institutions serving cannabis businesses, has passed the House multiple times but has not cleared the Senate. The MORE Act (Marijuana Opportunity Reinvestment and Expungement Act) would deschedule cannabis entirely but has not advanced beyond the House. Medical cannabis research-specific bills, including proposals to expand research access and streamline licensing, have been introduced but not enacted. Research funding represents a critical bottleneck. The National Institutes of Health budget for cannabis research remains modest compared to other therapeutic areas. Private funding from the cannabis industry has been limited. Philanthropic organizations have not prioritized cannabis research to the extent they have other medical research areas. Increased funding would enable larger, longer-duration trials with sufficient statistical power to detect clinically meaningful effects. Specific research priorities identified by experts include randomized controlled trials comparing cannabis to standard treatments for chemotherapy-induced nausea, pain, and cachexia; studies of optimal cannabinoid ratios and dosing regimens; investigation of drug interactions between cannabis and chemotherapy or other cancer medications; and long-term safety studies in cancer populations. The question of cannabis as an anti-cancer agent requires a different research approach. If cannabinoids have direct anti-tumor effects in humans, demonstrating this would require phase 1 dose-escalation trials to establish safety, followed by phase 2 trials to assess preliminary efficacy, and ultimately phase 3 randomized controlled trials comparing cannabinoid treatment to standard of care. This pathway would take years and cost hundreds of millions of dollars—investment that has not materialized. International research may advance faster than U.S. efforts. Israel, Canada, and several European countries have fewer regulatory barriers and more government support for medical cannabis research. Results from international trials could influence U.S. policy and practice, though FDA approval would still require U.S.-based trials. Patient access will likely continue to expand at the state level regardless of federal policy. Additional states may legalize medical cannabis programs, and existing programs may expand qualifying conditions or reduce restrictions. However, the fundamental tension between state and federal law will persist until Congress acts. The role of healthcare providers will evolve as evidence accumulates. Medical schools have begun incorporating cannabis education into curricula. Professional organizations are developing clinical guidance. However, many physicians remain reluctant to recommend cannabis due to federal prohibition, liability concerns, and limited evidence. Increased research and clearer legal frameworks could change this dynamic.

Further Reading and Primary Sources

• National Cancer Institute: Cannabis and Cannabinoids (PDQ®)–Health Professional Version - https://www.cancer.gov/about-cancer/treatment/cam/hp/cannabis-pdq
• National Academies of Sciences, Engineering, and Medicine: The Health Effects of Cannabis and Cannabinoids (2017) - https://www.nationalacademies.org/our-work/the-health-effects-of-cannabis-and-cannabinoids
• American Society of Clinical Oncology: Marijuana Use in Oncology - https://www.asco.org/advocacy-policy/asco-in-action/marijuana-use-in-oncology
• Drug Enforcement Administration: Drug Scheduling - https://www.dea.gov/drug-information/drug-scheduling
• Food and Drug Administration: FDA and Cannabis: Research and Drug Approval Process - https://www.fda.gov/news-events/public-health-focus/fda-and-cannabis-research-and-drug-approval-process
• University of California Center for Medicinal Cannabis Research - https://www.cmcr.ucsd.edu/
• Controlled Substances Act, 21 U.S.C. § 812 - https://www.govinfo.gov/content/pkg/USCODE-2011-title21/html/USCODE-2011-title21-chap13-subchapI-partB-sec812.htm
• Agriculture Improvement Act of 2018 (Farm Bill) - https://www.congress.gov/bill/115th-congress/house-bill/2
• Journal of Clinical Oncology: Systematic Review of Cannabinoids for Nausea and Vomiting (2015) - https://ascopubs.org/journal/jco
• American Cancer Society: Marijuana and Cancer - https://www.cancer.org/treatment/treatments-and-side-effects/treatment-types/complementary-and-integrative-medicine/marijuana-and-cancer.html